Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

OBJECTIVE: To explore the clinical efficacy and safety of subcutaneous (SC) rozanolixizumab, an anti-neonatal Fc receptor humanized monoclonal antibody, in patients with generalized myasthenia gravis (gMG). METHODS: In this phase 2a, randomized, double-blind, placebo-controlled, 2-period, multicente...

Descripción completa

Detalles Bibliográficos
Autores principales: Bril, Vera, Benatar, Michael, Andersen, Henning, Vissing, John, Brock, Melissa, Greve, Bernhard, Kiessling, Peter, Woltering, Franz, Griffin, Laura, Van den Bergh, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105899/
https://www.ncbi.nlm.nih.gov/pubmed/33219142
http://dx.doi.org/10.1212/WNL.0000000000011108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105899/
https://www.ncbi.nlm.nih.gov/pubmed/33219142
http://dx.doi.org/10.1212/WNL.0000000000011108

Ejemplares similares